Steroid-enhancing selective casein kinase inhibitors: first in class novel inhaled anti-asthma agents

类固醇增强选择性酪蛋白激酶抑制剂：同类首创的新型吸入式抗哮喘药物

• 批准号: nhmrc : GNT1137171
• 负责人: Dr Colin Barrett
• 金额: $ 53.81万
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/steroid-enhancing-selective-asthma-agents/1348084
• 关键词: Steroid; enhancing; selective; casein; kinase

Chronic lung diseases reduce quality and duration of life of 0.5 billion globally (1 in 4 Australians). Current drugs fail to adequately reduce the decline in lung function. This development is based on the discovery of an enzyme pathway contributing to poor lung function. The project will identify the best doses of the drug and the best combinations with existing drugs to reduce the lung scarring and inflammation. These new findings support efforts to secure investment for clinical testing.

慢性肺部疾病降低了全球5亿人的生活质量和寿命（四分之一的澳大利亚人）。目前的药物不能充分减少肺功能的下降。这一进展是基于一种导致肺功能不良的酶途径的发现。该项目将确定药物的最佳剂量以及与现有药物的最佳组合，以减少肺部疤痕和炎症。这些新发现支持了确保临床试验投资的努力。